<DOC>
	<DOCNO>NCT00248313</DOCNO>
	<brief_summary>To assess equivalence rate functional graft survival 12 month transplantation patient receive induction therapy cyclosporin ( CsA , Neoral ) Rapamune® follow CsA dose reduction concentration-controlled Rapamune® versus induction CsA Rapamune® follow discontinuation CsA concentration-controlled Rapamune® .</brief_summary>
	<brief_title>Study Comparing Cyclosporin Dose Reduction With Cyclosporin Elimination Kidney Transplant Recipients Taking Sirolimus</brief_title>
	<detailed_description />
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<criteria>Age : = ≥ 18 year . Endstage renal disease , patient schedule receive primary secondary renal allograft cadaveric donor , livingunrelated donor , livingrelated donor . Patients second subsequent transplant must maintain primary graft least 6 month transplantation ( exception graft failure due technical reason ) . Evidence active systemic localise major infection prior initial Rapamune® administration . Evidence infiltrate , cavitation , consolidation chest xray obtain screen . Use investigational drug treatment 4 week prior enrol study 12month treatment phase . Exception : use erythropoiesis stimulating product . In case , erythrocytestimulating product must discontinue prior administration Rapamune® .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2007</verification_date>
	<keyword>Kidney Disease</keyword>
</DOC>